drugset / Trial / NCT03379311
A Study of AK002 in Patients With Atopic Keratoconjunctivitis, Vernal Keratoconjunctivitis, and Perennial Allergic Conjunctivitis
NaSingle-groupOpen-labelOther
Summary
This is a Phase 1b, open-label, study to assess the effects of AK002, given as monthly intravenous infusion for 6 doses at up to 3 mg/kg.
Timeline
- Start
- 2018-02-26
- Primary completion
- 2019-08-08
- Completion
- 2019-08-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | lirentelimab | Monoclonal antibody | 3 mg/kg | Intravenous |